Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Bone Marrow Quality Index to assess the safety of HSCT in thalassemia

Lawrence Faulkner, MD, Cure2Children Foundation, Florence, Italy, discusses his recent publication on the use of a bone marrow quality index to predict graft-versus-host disease (GvHD) in hematopoietic stem cell transplantation (HSCT) for thalassemia. This interview was held at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.